abstract |
The present invention generally relates to (a) at least 50 mg / mL hemopexin content; (b) at least 15 mM phosphate buffer; (c) pH 5.8-8 and (d) at least 50 mM sodium chloride. Containing stable liquid formulations of purified hemopexin, including, and its use. |